i26 Hyperimmune Egg Powder
This is i26 in its purest form with no additional ingredients. Made with 100% specific immunity egg protein, i26 should be taken 1-2 times daily for improved digestive function. By targeting bad bacteria and improving gut integrity, i26 supports a responsive immune system for improved well being.
- Increase daily energy
- Reduce digestive sensitivity
- Reduce severity of allergies
- Improve oral health
- Improve joint mobility
Reduce symptoms of poor digestive health including:
- Acid Reflu
Versatile delivery options:
Add it to milk, yogurt, cereal, ice cream, a smoothie, or try some of our no-bake snack recipes!
NOTE: Adding i26 to hot liquids may damage and destroy the active immune proteins in i2
- Serving Size: 1 scoop (4.5 g)
- Servings per Container: 31
- Amount Per Serving (%DV*)
- Calories: 21.5 1.1%
- Calories from Fat: 13 *
- Total Fat: 1.5g 2.2%
- Saturated Fat: 0.6g 2.9%
- Cholesterol: 75.6 mg 25%
- Protein: 2g 4.1%
*Percent Daily Values are based on a 2,000-calorie diet.
Nigiro Blue Tint
A Patented formula, Non-Prescription Nutrient Shown in Laboratory Tests to Possess Significant Anti-Viral Properties
Demonstrated to be 12 Times More Effective Than the Yellow Pills Against Tested Strains of Influenza Virus Type A;
Demonstrated to be effective against Influenza Virus Type B, Hand-Foot-Mouth Disease (HFMD) – Enterovirus 71 and Coxsackie A16; and other Viral Pathogens;
Extensive laboratory testing reported in peer reviewed scientific literature;
100% organic and natural, derived from an organic nutritive resource with Naturland organic certification, Germany;
Produced Under Strict International ISO 9001:2000 Quality Assurance Guidelines. Adhere to International GMP standard.
Safe and non-toxic, even at high dosage levels.
Ideal for Travel, Work, and Home
Suitable for Both Adults and Children
Under license to distribute exclusively from
Green Energy Biotech Corporation Limited
Peroxisome proliferator-activated receptor ( PPARs )
In the field of molecular biology, the peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms.
- Three types of PPARs have been identified: alpha, gamma, and delta (beta):
- PPAR α (alpha) – expressed in liver, kidney, heart, muscle, adipose tissue, and others
- PPAR β/δ (beta/delta) – expressed in many tissues but markedly in
- brain, adipose tissue, and skin
PPAR γ (gamma) – although transcribed by the same gene, this PPAR through alternative splicing is expressed in three forms:
- γ1 – expressed in virtually all tissues, including heart, muscle, colon, kidney, pancreas, and spleen
- γ2 – expressed mainly in adipose tissue (30 amino acids longer)
- γ3 – expressed in macrophages, large intestine, white adipose tissue
PPAR agonists are drugs which act upon the peroxisome proliferator-activated receptor. They are .used for the treatment of symptoms of the metabolic syndrome, mainly for lowering triglycerides and blood sugar
PPARα (alpha) is the main target of fibrate drugs, a class of amphipathic carboxylic acids (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate). They were originally indicated for cholesterol disorders and more recently for disorders that feature high triglycerides.
PPARγ (gamma) is the main target of the drug class of thiazolidinediones (TZDs), used in diabetes mellitus and other diseases that feature insulin resistance. It is also mildly activated by certain NSAIDs (such as ibuprofen) and indoles, as well as from a number of natural compounds. Known inhibitors include the experimental agent GW-9662.
They are also used in treating hyperlipidaemia in atherosclerosis. Here they act by increasing the expression of ABCA1, which transports extra-hepatic cholesterol into HDL. Increased uptake and excretion from the liver therefore follows.
Animal studies have shown their possible role in amelioration of pulmonary inflammation, especially in asthma.
PPARδ (delta) is the main target of a research chemical named GW501516. It has been shown that agonism of PPARδ changes the body’s fuel preference from glucose to lipids, but ironically improves metabolic syndrome (which is characterized by the body being unable to efficiently deal with glucose resulting in insulin resistance and sometimes diabetes).
Dual and pan PPAR agonists
The fourth class of dual PPAR agonists, so-called glitazars, which bind to both the α and γ PPAR isoforms, are currently under active investigation for the treatment of a larger subset of the symptoms of the metabolic syndrome. These include the experimental compounds aleglitazar, muraglitazar, and tesaglitazar. In June 2013, saroglitazar was the first glitazar to be approved for clinical use.
In addition, there is continuing research and development of new dual α/δ and γ/δ PPAR agonists for additional therapeutic indications, as well as “pan” agonists acting on all three isoforms.